Tislelizumab

Tislelizumab plus chemotherapy demonstrated statistically significant and clinically meaningful improvements in OS vs. chemotherapy alone among patients with PD-L1-positive, advanced gastric or gastroesophageal junction adenocarcinoma.

A phase 3 trial of the PD-1 inhibitor tislelizumab met its primary endpoint of noninferior OS compared with sorafenib as first-line treatment for adults with unresectable hepatocellular carcinoma, according to the agent’s manufacturer.

The addition of tislelizumab to first-line chemotherapy extended OS among patients with advanced esophageal cancer, according to study results presented at European Society for Medical Oncology World Congress on Gastrointestinal Cancer.

The addition of tislelizumab to chemotherapy significantly extended OS for patients with previously untreated advanced esophageal squamous cell carcinoma, according to a press release from the agent’s manufacturer.

The addition of tislelizumab to chemotherapy conferred a clinically meaningful PFS benefit among patients with recurrent or metastatic nasopharyngeal cancer, according to updated results of the randomized phase 3 RATIONALE-309 study.

Tislelizumab improved overall survival compared with investigator-chosen standard chemotherapy in patients with esophageal squamous cell carcinoma, according to data from a phase 3 study presented at ASCO21.

The addition of tislelizumab to chemotherapy led to improvements in PFS among patients with advanced squamous cell non-small cell lung cancer, according to results of the randomized phase 3 study published in JAMA Oncology.

Tislelizumab extended OS compared with chemotherapy for patients with previously treated advanced esophageal squamous cell carcinoma, according to topline data released by the agent’s manufacturer.

Tislelizumab prolonged OS compared with docetaxel for patients with advanced non-small cell lung cancer, according to topline data released by the agent’s manufacturer.

The addition of tislelizumab to first-line chemotherapy extended PFS among patients with nonsquamous non-small cell lung cancer, according to topline data from a randomized phase 3 trial released by the agent’s manufacturer.